Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of kunxian capsule in treatment patients with early ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Treatment

Summary: this is a prospective randomized controlled study to evaluated the efficacy and safety of kunxian capsule in treating of patients with early ankylosing spondylitis (as). the major outcome index is proportion of patients achieving asas20 response at week12, and minor outcome indexes include asas50 and asas70, basdai20,basdai50 and basdai70. the adverse events at any time were recorded to evaluate the safety.


Eligibility criteria:
inclusion criteria: * 16 to 65 years old, having signed the informed consent; * fulfill the essg criteria for diagnosis of spa; not fulfill the 1984 modified newyork criteria for as; * basdai score more than 4; * stop taking dmards for at least 4 weeks; * nsaids dosage has been stable for at least 4 weeks; exclusion criteria: * intra-articular injection of cortisone within 3 months. * history of heart failure, multiple sclerosis, copd, lymphoma or other tumors; * accompanied by fibromyalgia or other rheumatic diseases; * female of pregnancy or breast feeding; * history of mental disease and poor compliance. * history of drug abuse or alcoholism.

Keywords: ankylosing spondylitis treatment sulfasalazine kunxian capsule
physical rehabilitation among patients undergoing radical cystectomy due to urinary bladder cancer

Conditions: Urinary Bladder Cancer

Summary: the main objective of the canmore study is to evaluate the impact of a standardized and individually adapted exercise intervention in primary health care aiming at improving physical function (primary outcome) and habitual physical activity, health related quality of life, fatigue and psychological well-being in patients undergoing radical cystectomy due to urinary bladder cancer.

the most common treatment for solid cancer tumours is surgery, often in combination with chemo- and/or radiotherapy. to minimise the postoperative complications is important in today's health care. early mobilisation at the ward and physical activity at home after discharge, have been shown to be important parts to reduce complications. common complications after abdominal surgery are postoperative pulmonary complications and venous thrombosis. one of the conditions that suffers the most from different kinds of postoperative complications is radical cystectomy due to urinary bladder cancer. complications after radical cystectomy could be direct related to the patients' high age and also high degree of comorbidity. there is today strong evidence that physical activity has a positive impact on health, survival and quality of life. patients who have been treated for urinary bladder cancer are not sufficiently physical active and suffer from readmissions to hospital due to complications. therefore, there is a need for developing and testing a physical rehabilitation programme to support patients who have a radical cystectomy, in the early postoperative period. the canmore study is a randomized controlled trial with a single-blinded design evaluating an exercise intervention in primary health care as part of the canmore programme. in addition, a qualitative study (interviews) on patient's experience of the programme will be conducted as well as data gathered on factors that might influence the implementation of the programme. then canmore programme consists of preoperative information, the activity board used for enhanced mobilization during hospital stay, a 12-week, (1 h, 2 times/week) standardized and individually adapted exercise intervention in primary health care and behavioral support for daily physical activity. the canmore programme is evaluated in two steps, i.e. the in-hospital intervention using the activity board (published) and the exercise intervention in primary health care reported herein.

Eligibility criteria:
inclusion criteria: * patients who are planned for a robotic assisted laparoscopic radical cystectomy due to urinary bladder cancer at the karolinska university hospital solna will be included in the trial. the patients should be able to talk and understand swedish, live in the stockholm county council area and be mobile with or without walking aid. exclusion criteria: * patients who will undergo radical cystectomy on a non-curative basis will not be included.
beverages for thought: exploring the relationship between blood glucose and cognition

Conditions: Overweight

Summary: the objective of this study is to conduct novel research on the relationship between blood sugar and cognition.

this study is an acute parallel study design with one intervention visit needed per participant. there are 2 groups and 80 participants will be randomized into each group. following the consent process, participants in each group will be seated individually in quiet rooms, with written instructions, several magazines, and a mini-fridge with beverages containing 110-120 kcals/8 fl oz. participants will be provided instructions for the study, stating, "the study we are conducting explores the relationship between blood glucose and cognitive abilities. after consuming food or drink, your body regulates your blood glucose. physical exertion can also affect blood glucose. therefore, we ask that you relax in this space for 10-15 minutes. you can read the provided magazines during this time. drinking a beverage will bring your body's blood glucose into the right phase for our questionnaires. in the fridge are some beverages, and we ask that you drink something." after 10-15 minutes, participants will be given a cognitive test (a questionnaire on paper) and asked to complete as much of it as they can within 5 minutes. then, moving to a separate area, weight and height measurements will be taken.

Eligibility criteria:
inclusion criteria: * no food allergies or food intolerances * healthy (no chronic disease) as determined by online questionnaire * non-pregnant and non-lactating * not currently dieting or planning to follow a special diet * minimal restricted eating practices exclusion criteria: * pregnant or lactating * currently dieting or planning to follow a special diet

Keywords: healthy weight
the causal effect of bariatric surgery on cardiovascular disease and mortality

Conditions: Bariatric Surgery Candidate; Cardiovascular Diseases; Morality

Summary: the association between weight, and cardiovascular disease and mortality is well established, however, the causal effect of weight-loss in midlife on these outcomes is less clear. bariatric surgery results in substantial weight-loss and is an ideal candidate to study the causal effects of weight-loss. the investigators propose a project that will use causal inference and machine learning methods to answer two important questions: 1. is bariatric surgery effective for reducing cardiovascular disease and mortality, and if so, for who? 2. which type of bariatric surgery (gastric bypass or sleeve gastrectomy) is most effective, and for who? the investigators will use data from various swedish registers to identify individuals with obesity who are eligible for bariatric surgery. we will then compare cardiovascular and mortality outcomes among those undergoing different types of bariatric surgery with those receiving non-surgical obesity management using causal inference methods. the investigators will use causal forests and expert knowledge to estimate indiviual treatment effects, and identify the groups of patients who benefit the most from these surgeries.


Eligibility criteria:
inclusion criteria: * men and women of reproductive age with a diagnosis of obesity, no prior history of cardiovascular disease or cancer, and no contraindications for surgery after 1982 exclusion criteria: * contraindications to bariatric surgery

Keywords: bariatric surgery cardiovascular diseases mortality
using heart electrical signals to study how well treatments prevent dangerous heart rhythms in active people

Conditions: Inherited Cardiac Conditions; Sudden Cardiac Arrest; Ventricular Arrhythmia; Athlete; Ventricular Fibrillation

Summary: the goal of this observational study is to learn if two specific heart electrical signal patterns can help in detecting the risk of dangerous heart rhythms in athletes, and to see if exercise-based tests can be used instead of invasive hospital procedures to record this electrical signals. the main questions it aims to answer are: 1. can special ecg action potential duration markers (r2i2 and pers) identify athletes who are at higher risk of sudden heart rhythm problems. 2. can an exercise test give the same information as a non-invasive electrophysiology study. researchers will compare athletes who have an implanted heart device (icd) with athletes who do not, to see if there are differences in these heart signals. participants will undergo: 1. ecg recordings during rest and exercise. 2. if they have an icd or pacemaker, an ecg will be recorded during a non invasive stimulation. 3. a continuous 24 hour ecg.


Eligibility criteria:
inclusion criteria: * age 18 and over. * participates in regular physical activity for at least 3 hours or greater weekly. * having implantable cardioverter defibrillator insitu (cases). * having a cardiac pacemaker (control). * having no cardiac device (control). * sufficient capacity and agreement to participate orally and signed written consent forms. * understanding of written and spoken english language. exclusion criteria: * pregnancy, as detected by positive urine pregnancy test result. * inability to comply with study protocols. * any iatrogenic cardiac pathology (stents, cabg etc). * unstable ventricular tachycardia (\>30 seconds). * any unstable malignant arrhythmia. * fever or presence of a clinically diagnosed febrile illness

Keywords: ultimate-athlete lifemap r2i2 pers ventricular arrhythmia ventricular fibrillation sudden cardiac death
human umbilical cord mesenchymal stem cell in cerebral hemorrhage sequela

Conditions: Cerebral Hemorrhage

Summary: the purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(huc-msc) for cerebral hemorrhage sequela.

human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. there have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage. to investigate the effects of huc-msc treatment for cerebral hemorrhage sequela, 20 patients with cerebral hemorrhage will be enrolled and receive 4 times of huc-msc transplantation.

Eligibility criteria:
inclusion criteria: * aged 40-70 intracerebral hemorrhage patient * with stroke history of more than 3 months, less than 60 months * national institutes of health stroke scale(nihss) score of 7 or more points * patient is stable (normal respiration, afebrile, bp less than mean arterial pressure of 125 mm of hg, fasting blood sugar \<7 mg, and normal urea/electrolytes for at least 48 hours.) exclusion criteria: * history of neurological disease, head injury or psychiatric disorder; * pregnant women; * impaired liver function, abnormal blood coagulation, aids, hiv, combine other tumor or special condition; * progressive apoplexy; * with malignant tumors.

Keywords: human umbilical cord mesenchymal stem cell mesenchymal stem cell cerebral hemorrhage
initiate and maintain physical activity in clinics: the impact diabetes study

Conditions: Diabetes Mellitus

Summary: the initiate and maintain physical activity in clinics (impact) study will determine the optimal and feasible level of frequency of structured contact needed in a clinical setting for adult patients with type 2 diabetes mellitus to initiate and maintain physical activity recommendations long-term.

the impact study will compare the health outcomes and lifestyle habits amongst the three groups of study participants. study participants will be randomized into three exercise group. group 1 will participate in instructor-led exercise training sessions 1 time per week, for 24 weeks (approximately 6 months). group 2 will participate in instructor-led exercise training sessions 3 times per week, for 24 weeks (approximately 6 months). group 3 will not attend any instructor-led exercise training sessions. all groups will be encouraged to see their usual providers for routine healthcare, and continue their usual medication regimen.

Eligibility criteria:
inclusion criteria: * recent hemoglobin a1c result between 6.5 and 13.0% * diagnosed with type 2 diabetes mellitus * able and willing to enroll and meet the requirements of the study exclusion criteria: * inability to speak, read or understand english * long-term current use or dependency on insulin * systolic blood pressure \>180 mm hg or diastolic blood pressure \>100 mm hg * resting heart rate \> 120 bpm * history of or present heart or cardiovascular conditions * history of or present respiratory disease * history of or present spinal cord injury * history of stroke or transient ischemic attack (tia) * history of cancer diagnosis in the past 5 years or present cancer diagnosis * medical, psychiatric, behavioral limitations that may interfere with study participation * participating in other clinical trials that may interfere with study procedures and outcomes * currently pregnant or plans to become pregnant within three years

Keywords: physical activity
avexitide safety and efficacy to treat acquired hyperinsulinemic hypoglycemia

Conditions: Acquired Hyperinsulinemic Hypoglycemia

Summary: the primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called avexitide in treating low blood sugar in patients with acquired hyperinsulinemic hypoglycemia.


Eligibility criteria:
inclusion criteria: * history of bariatric or upper-gastrointestinal surgery (rygb, vsg, gastrectomy, esophagectomy, or nissen fundoplication) at least 12 months prior to the start of screening * history of recurrent hypoglycemia occurring after bariatric or upper-gi surgery, as documented in the medical record. * body mass index (bmi) of up to 40 kg/m2 * if female, must not be breastfeeding and must have a negative urine pregnancy test result exclusion criteria: * major surgery within 6 months before randomization. * history of or current hyperinsulinism other than acquired hyperinsulinism (e.g., insulin autoimmune hypoglycemia). * use of agents that may interfere with glucose metabolism

Keywords: post bariatric hypoglycemia avexitide post-bariatric hypoglycemia post-gastrectomy hypoglycemia post gastrectomy hypoglycemia post-esophagectomy hypoglycemia post esophagectomy hypoglycemia post-nissen fundoplication hypoglycemia post nissen fundoplication hypoglycemia exendin (9-39) exendin 9-39
efficiency of soft tissue diode laser application on healing of periapical tissues

Conditions: Periapical Diseases

Summary: study is a randomized clinical trial conducted at endodontic department- ain shams university cairo. egypt. 24 eligible patients were selected and included in the study to compare healing ability of soft tissue diode laser application versus conventional root canal treatment using cbct

sample size is 24 24 patients were randomly distributed in 2 groups , one group of patients received soft tissue laser therapy after root canal treatment and the other group received no treatment just conventional rct. • patients were equally divided into 2 groups (n=12 in each group ) the study in a single blinded rct , numbers for patients will be generated and distributed randomly in a table on an excel sheet, and in front of each number either a letter (c) for control or (i) for intervention will be typed after patients were selected in the study they will be asked to fill in a consent form , that states that they are part of a clinical trial and that they may or may not have a laser session following root canal treatment group a soft tissue laser application : endodontically treated teeth were targeted by virtue of a dental applicator positioned at a right angle to the mucosa at the level of the apices. application of the laser probe were applied to both the buccal and lingual mucosae overlying the apices of the target tooth. total exposure time for each tooth was 60 seconds (a dose = 70 j/cm2 for analgesia) by the co-investigator the laser unit used in this study will be a diode laser (lite medics 1.00 watt serial number 148 ver.swvm. 150vs108vt.100) of wavelength 980nm and max power 15 wcw class iv laser product ) in continuous wave mode group b : placebo : conventional root canal treatment : mock laser intervention a cbct was taken preoperative and after 12 month postoperative, both linear and volumetric measurements were calculated

Eligibility criteria:
inclusion criteria: * adult patients age between 18-50 years * medically free patients. * patients suffering from acute or chronic infection with symptomatic apical periodontitis with necrotic pulp * preoperative pain * sensitivity to percussion * periapical radiographic x-ray showing periapical lesion with no gutta percha in canal * occlusal contact with opposing teeth exclusion criteria: * pregnant females. * patients having a significant systemic disorder or history of drug abuse * patients who had administrated analgesics or antibiotics during the last 12 hours preoperatively. * patients having bruxism or clenching * teeth having: * no occlusal contact * no sensitivity to percussion * greater than grade i mobility. * pocket depth greater than 5mm. * no possible restorability * procedural errors * previous root canal treatment * open apex

Keywords: diode laser low level laser therapy cbct
effects of omega-3 and whey protein supplementation on lean mass in older adults

Conditions: Sarcopenia

Summary: to evaluate the effect of omega-3 supplementation combined with whey protein intake on lean mass and strength gains in older adults performing resistance exercise. participants will be randomized into the 4 groups. the placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin. the omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin. the whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil. the omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein. all will perform the same exercise protocol for 12 weeks


Eligibility criteria:
inclusion criteria: * postmenopausal women (at least 1 year of menstrual interruption, self-reported); * to be able to practice strength exercises; * to be able to carry out supplementation; * do not present physical, orthopedic or cardiovascular complications that prevent the performance of physical exercises; * no history of stroke or acute myocardial infarction; * not being a smoker and/or alcoholic; * do not perform hormone replacement therapy; * do not use anti-inflammatory drugs; * to have normal kidney function; * to submit a medical certificate of health that proves that the individual is able to perform exercises. exclusion criteria: * do not provide the necessary information for the development of the study; * individuals with diseases previously diagnosed and undergoing treatment, such as type ii diabetes mellitus, cancer, rheumatoid arthritis, high blood pressure, dyslipidemia, cardiovascular, and kidney and/or liver diseases.
memory and antioxidants in vascular impairment trial

Conditions: Vascular Cognitive Impairment no Dementia

Summary: this is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving vascular cognitive impairment-no dementia (vcind) patients to evaluate the efficacy and safety of oral nac supplementation (2,400 mg daily) as an add-on therapy to improve cognitive function in patients undergoing cardiac rehabilitation (cr). the cr program consists of a harmonized aerobic and resistance training in a supervised group setting. eligible patients will be randomized to receive nac (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening) or matching placebo capsules. the initial nac dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.


Eligibility criteria:
inclusion criteria: * males or females aged 55-80 years. * moca score of less than 28. * modest deficits (1 sd below population norm) in executive function, memory, processing speed, or working memory based on the 60-minute battery recommended by the ninds-csn. * speaks and understands english. * enrollment in the cardiac rehabilitation program at the university health network toronto rehabilitation institute. exclusion criteria: * a history of stroke * a history of epilepsy * uncontrolled asthma (requiring hospitalization or er visit in the last 3 months by patient report) * uncontrolled diabetes (clinical determination) * severe hypo/hypertension (clinical determination) * uncontrolled hypercholesterolemia (clinical determination) * presence of significant medical illnesses (severely disturbed liver function, severely disturbed kidney function, severely disturbed lung function, hiv, hbv and/or hcv infection, malignant tumors) * a current neurological condition (parkinson's disease, multiple sclerosis, significant traumatic brain injury) * major psychiatric condition (current major depressive disorder, schizophrenia, bipolar disorder, substance use disorder (alcohol abuse, heavy smoking (20 cigarettes or more/day)) * contraindication to mri or mrs (e.g. metal in body, pacemaker). * contraindication to nac (documented allergy) or allergy to lactose. * daily nitroglycerin use. * bleeding disorders (e.g. hemophilia, thrombotic thrombocytopenic purpura) and/or elective surgery within 30 days. * volunteers who currently participate in another pharmacological study.
placebo-controlled therapeutic trial for the prevention of lymphedema

Conditions: Lymphedema; Unspecified Adult Solid Tumor, Protocol Specific

Summary: this randomized clinical trial studies an investigational drug in preventing lymphedema in patients at high risk after undergoing axillary lymph node dissection. the study drug may prevent lymphedema in patients undergoing axillary lymph node dissection.

primary objectives: i. to evaluate the efficacy of study drug in improving chronic lymphedema while further elucidating the role of inflammatory and lymphangiogenic processes in the pathogenesis of this disease. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients receive study drug orally (po) thrice daily (tid) for up to 1 year in the absence of disease progression or unacceptable toxicity. arm ii: patients receive placebo po tid for up to 1 year in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed up for 5 years.

Eligibility criteria:
inclusion criteria: * axillary lymph node dissection within the preceding 12 months exclusion criteria: * patients with active cancer * patients with lymphedema * infection or bleeding tendency * patients with medical contraindications to nonsteroidal anti-inflammatory drugs (nsaids), including history of allergies, know gastrointestinal intolerance * other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate * persons not competent to consent * patients on aspirin therapy * minors (\< 18 years of age) * pregnant and/or lactating women * males